marketcaparena
Search

    SNGX

    SOLIGENIX, INC.

    Company overview

    Market capitalization
    $8.21M
    Employees
    13
    Latest publication
    2026-09-29
    About SOLIGENIX, INC.

    Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue0USD0USD0USD0USD0USD6,352USD-6,352USD2,342USD
    Cost Of Revenue1,098USD1,000USD0USD703USD608USD3,175USD3,176USD2,342USD
    Gross Profit-1,098USD-1,000USD0USD-703USD-608USD3,176USD-1,589USD-2,342USD
    Research Development1,781,202USD2,283,240USD1,583,879USD1,677,014USD2,227,175USD2,658,702USD968,689USD501,158USD
    Selling General Administrative1,102,538USD1,191,366USD996,604USD1,086,865USD1,084,828USD1,053,793USD896,547USD1,243,517USD
    Total Operating Expenses2,883,740USD3,473,604USD2,580,483USD2,763,879USD3,312,003USD3,712,495USD1,865,236USD1,742,333USD
    Operating Income-2,884,838USD-3,474,606USD-2,580,483USD-2,763,879USD-3,312,003USD-3,712,495USD-1,865,236USD-1,744,675USD
    Net Interest Income61,389USD71,968USD52,351USD69,823USD76,028USD70,372USD78,836USD35,925USD
    Income Before Tax-2,824,965USD-3,402,804USD-2,530,947USD-2,701,976USD-3,236,763USD-3,396,480USD-1,719,381USD-1,644,502USD
    Net Income-2,824,965USD-2,896,189USD-2,530,947USD-2,701,976USD-3,236,763USD-2,987,366USD-1,719,381USD-1,644,502USD
    Net Income From Continuing Ops-2,824,965USD-2,896,189USD-2,530,947USD-2,701,976USD-3,236,763USD-2,987,366USD-1,719,381USD-1,644,502USD
    Ebit-2,884,838USD-3,474,606USD-2,530,947USD-2,763,879USD-3,312,003USD-3,712,495USD-1,865,236USD-1,776,494USD
    Ebitda-2,883,740USD-3,473,604USD-2,530,036USD-2,763,176USD-3,311,395USD-3,711,446USD-1,863,647USD-1,774,906USD
    Depreciation And Amortization1,098USD1,002USD911USD703USD608USD1,049USD1,589USD1,588USD
    Reconciled Depreciation1,098USD1,002USD911USD703USD608USD1,049USD1,589USD1,588USD
    Total Other Income Expense Net59,873USD71,802USD49,536USD61,903USD75,240USD316,015USD145,855USD100,173USD
    Income Tax Expense—-506,615USD———-409,114USD-25,488USD31,819USD
    Interest Income———69,823USD———35,925USD
    Tax Provision—————-409,114USD0USD0USD
    Interest Expense——————78,836USD35,925USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue0USD119,371USD839,359USD250,000USD33,351USD1,930,533USD3,215,639USD5,241,000USD
    Cost Of Revenue0USD119,371USD742,048USD550,822USD728,640USD1,820,949USD3,567,415USD4,598,000USD
    Gross Profit0USD-119,371USD-742,048USD-300,822USD-695,289USD109,584USD-351,776USD643,733USD
    Research Development7,485,813USD5,223,589USD3,312,699USD7,944,089USD8,185,850USD14,796,167USD8,122,610USD6,751,000USD
    Selling General Administrative4,359,663USD4,215,908USD4,482,552USD6,692,904USD5,008,738USD4,328,838USD3,480,912USD2,952,000USD
    Total Operating Expenses11,845,476USD9,320,126USD6,955,892USD13,938,082USD12,403,671USD18,696,091USD10,189,245USD8,427,000USD
    Operating Income-11,845,476USD-9,439,497USD-7,697,940USD-14,238,904USD-13,098,960USD-18,586,507USD-10,541,021USD-9,059,000USD
    Net Interest Income270,170USD213,975USD-278,242USD-822,611USD-862,577USD-10,882USD148,968USD159,006USD
    Income Before Tax-11,586,995USD-8,675,690USD-7,908,533USD-14,953,274USD-13,415,715USD-18,525,415USD-9,966,268USD-8,900,000USD
    Income Tax Expense-506,615USD-409,114USD-1,767,803USD-1,154,935USD-864,742USD-836,893USD-610,676USD159,006USD
    Tax Provision-506,615USD-409,114USD-1,161,197USD-1,154,935USD-864,742USD-836,893USD-610,676USD0USD
    Net Income-11,080,380USD-8,266,576USD-6,140,730USD-13,798,339USD-12,550,973USD-17,688,522USD-9,355,592USD-8,900,000USD
    Net Income From Continuing Ops-11,080,380USD-8,266,576USD-8,074,390USD-13,798,339USD-12,550,973USD-17,688,522USD-9,355,592USD-8,899,975USD
    Ebit-11,848,700USD-9,464,985USD-7,674,156USD-14,130,663USD-12,511,213USD-18,514,533USD-10,107,427USD-9,059,060USD
    Ebitda-11,845,476USD-9,459,171USD-7,667,602USD-14,106,101USD-12,477,052USD-18,452,161USD-10,052,977USD-9,015,000USD
    Depreciation And Amortization3,224USD5,814USD6,554USD24,562USD34,161USD62,372USD54,450USD44,060USD
    Reconciled Depreciation3,224USD5,814USD7,988USD24,562USD34,161USD62,372USD54,450USD44,060USD
    Total Other Income Expense Net258,481USD763,807USD-210,593USD-714,370USD-316,755USD61,092USD574,753USD159,006USD
    Interest Expense—213,975USD49,129USD822,611USD904,502USD10,882USD133,350USD0USD
    Net Income Applicable To Common Shares————-12,550,973USD-17,688,522USD-9,355,592USD-8,899,975USD
    Interest Income—————47,951USD148,968USD159,006USD
    Unclassified Operating Expenses——————-1,414,277USD-1,276,000USD
    Non Operating Income Net Other——————148,968USD159,006USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets10,499,470USD6,922,640USD9,235,521USD11,293,917USD5,760,647USD7,746,120USD8,966,483USD10,476,979USD
    Total Current Assets10,171,786USD6,565,248USD8,849,007USD10,880,913USD5,320,452USD7,640,742USD8,828,630USD10,306,892USD
    Total Liabilities3,853,913USD———————
    Total Current Liabilities3,671,839USD3,619,310USD3,699,275USD3,422,021USD3,629,107USD4,133,682USD4,848,412USD4,530,247USD
    Other Current Liabilities2,059,974USD———————
    Total Stockholder Equity6,645,557USD3,089,905USD5,292,125USD7,597,976USD1,828,951USD3,612,438USD4,118,071USD5,935,188USD
    Total Equity Including Noncontrolling Interest6,645,557USD———————
    Property Plant Equipment Net304,907USD326,940USD354,965USD390,227USD417,418USD82,601USD115,076USD147,310USD
    Accounts Payable1,407,298USD828,658USD1,115,497USD1,206,796USD649,955USD599,688USD667,896USD891,227USD
    Short Term Debt120,515USD117,235USD114,023USD111,134USD108,814USD79,125USD1,484,735USD2,191,423USD
    Common Stock21,637USD10,518USD10,086USD9,861USD3,505USD3,183USD2,514USD2,295USD
    Retained Earnings-249,863,451USD-247,876,097USD-245,051,132USD-242,154,943USD-239,623,996USD-237,207,515USD-233,970,752USD-230,983,386USD
    Accumulated Other Comprehensive Income45,789USD45,789USD45,789USD45,788USD45,789USD45,789USD45,789USD37,473USD
    Other Current Assets—535,818USD912,854USD355,578USD222,782USD343,571USD1,009,116USD466,715USD
    Total Liab—3,832,735USD3,943,396USD3,695,941USD3,931,696USD4,133,682USD4,848,412USD4,541,791USD
    Other Current Liab—2,673,417USD2,469,755USD2,104,091USD2,870,338USD3,454,869USD2,695,781USD1,447,597USD
    Capital Stock—10,518USD10,086USD9,861USD3,505USD3,183USD2,514USD2,295USD
    Cash—6,029,430USD7,936,153USD10,525,335USD5,097,670USD7,297,171USD7,819,514USD9,840,177USD
    Cash And Short Term Investments—6,029,430USD7,936,153USD10,525,335USD5,097,670USD7,297,171USD7,819,514USD9,840,177USD
    Net Debt—-5,698,770USD-7,578,009USD-10,140,281USD-4,686,267USD-7,218,046USD-6,334,779USD-7,637,210USD
    Short Long Term Debt Total—330,660USD358,144USD385,054USD411,403USD79,125USD1,484,735USD2,202,967USD
    Property Plant Equipment Gross—334,615USD363,737USD390,227USD417,418USD82,601USD115,076USD147,310USD
    Common Stock Shares Outstanding—10,164,898shares10,086,130shares4,329,649shares3,278,677shares3,050,000shares2,514,000shares2,204,000shares
    Non Current Assets Total—357,392USD386,514USD413,004USD440,195USD105,378USD137,853USD170,087USD
    Non Current Liabilities Total—213,425USD244,121USD273,920USD302,589USD3,454,869USD0USD11,544USD
    Non Currrent Assets Other—30,452USD31,549USD22,777USD22,777USD22,777USD22,777USD22,777USD
    Net Working Capital—2,945,938USD5,149,732USD7,458,892USD1,691,345USD3,507,060USD3,980,218USD5,776,645USD
    Unclassified Equity—250,899,177USD250,277,296USD249,687,409USD241,400,148USD240,767,798USD238,038,006USD236,876,511USD
    Unclassified Non Current Liabilities—————3,454,869USD——
    Short Long Term Debt——————1,372,873USD2,059,309USD
    Unclassified Current Liabilities——————-1,372,873USD-2,059,309USD
    Source0001104659-26-092681DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets9,235,521USD8,966,483USD9,797,326USD14,279,717USD26,869,927USD19,891,235USD7,775,360USD10,491,702USD
    Other Current Assets912,854USD1,009,116USD866,014USD274,209USD282,903USD225,473USD609,739USD157,278USD
    Total Liab3,943,396USD4,848,412USD7,274,904USD16,750,543USD16,147,329USD16,149,407USD6,318,225USD4,211,532USD
    Total Stockholder Equity5,292,125USD4,118,071USD2,522,422USD-2,470,826USD10,722,598USD3,741,828USD1,457,135USD6,280,170USD
    Other Current Liab2,469,755USD2,695,781USD2,669,117USD2,644,438USD3,259,481USD3,513,404USD3,455,559USD2,085,316USD
    Common Stock10,086USD2,514USD10,378USD2,909USD2,859USD30,644USD21,753USD17,683USD
    Capital Stock10,086USD2,514USD10,378USD2,909USD42,873USD30,644USD21,753USD17,683USD
    Retained Earnings-245,051,132USD-233,970,752USD-225,704,176USD-219,563,446USD-205,765,107USD-193,214,134USD-175,525,612USD-166,170,020USD
    Cash7,936,153USD7,819,514USD8,446,158USD13,359,615USD26,043,897USD18,676,663USD5,420,708USD8,983,717USD
    Cash And Short Term Investments7,936,153USD7,819,514USD8,446,158USD13,359,615USD26,043,897USD18,676,663USD5,420,708USD8,983,717USD
    Total Current Assets8,849,007USD8,828,630USD9,507,320USD13,853,152USD26,569,521USD19,467,006USD7,493,325USD10,342,710USD
    Total Current Liabilities3,699,275USD4,848,412USD6,152,108USD16,516,873USD6,291,176USD6,080,521USD6,312,076USD4,211,532USD
    Net Debt-7,578,009USD-6,334,779USD-4,951,597USD-3,119,349USD-16,081,593USD-8,170,504USD-5,293,484USD-8,983,717USD
    Short Term Debt114,023USD1,484,735USD2,371,765USD10,006,639USD106,151USD437,273USD121,075USD—
    Short Long Term Debt Total358,144USD1,484,735USD3,494,561USD10,240,266USD9,962,304USD10,506,159USD127,224USD—
    Accounts Payable1,115,497USD667,896USD1,111,226USD3,865,796USD2,925,544USD2,129,844USD2,735,442USD2,126,215USD
    Property Plant Equipment Net354,965USD115,076USD241,761USD359,468USD128,375USD251,537USD161,505USD19,634USD
    Property Plant Equipment Gross363,737USD115,076USD363,081USD474,234USD296,223USD251,537USD161,505USD19,634USD
    Accumulated Other Comprehensive Income45,789USD45,789USD22,243USD24,747USD41,942USD-24,337USD-45,010USD-3,669USD
    Common Stock Shares Outstanding5,188,799shares1,660,000shares484,877shares179,459shares185,797shares114,529shares80,735shares54,909shares
    Non Current Assets Total386,514USD137,853USD290,006USD426,565USD300,406USD424,229USD282,035USD148,992USD
    Non Current Liabilities Total244,121USD0USD1,122,796USD233,670USD9,856,153USD10,068,886USD6,149USD0USD
    Non Currrent Assets Other31,549USD22,777USD48,245USD67,097USD172,031USD172,692USD100,831USD82,495USD
    Net Working Capital5,149,732USD3,980,218USD3,355,212USD-2,663,721USD20,278,345USD13,386,485USD1,181,249USD6,131,178USD
    Unclassified Equity250,277,296USD238,038,006USD228,183,599USD217,062,055USD216,400,031USD196,919,011USD176,984,251USD172,418,493USD
    Short Long Term Debt—1,372,873USD2,250,000USD9,897,691USD—324,979USD——
    Unclassified Current Liabilities—-1,372,873USD-4,295,123USD-9,897,691USD————
    Current Deferred Revenue——2,045,123USD—————
    Long Term Debt——1,010,934USD—9,856,153USD9,952,590USD6,149USD—
    Net Receivables——195,148USD219,328USD242,721USD564,870USD1,462,878USD1,201,715USD
    Inventory——1USD1USD——2USD1USD
    Intangible Assets————7,750USD23,250USD19,699USD46,863USD
    Deferred Long Term Liab————20,266USD53,523USD39,324USD59,761USD
    Other Assets————172,031USD149,442USD62,081USD82,495USD
    Net Tangible Assets————10,722,598USD3,718,578USD1,398,686USD6,233,307USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Stock Based Compensation237,180USD
    Other Non Cash Items58,443USD
    Operating Cash Flow-4,064,414USD
    Financing Cash Flow5,939,402USD
    Change In Cash1,874,988USD
    End Cash Flow9,811,141USD
    Source0001104659-26-092681DeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-2,800,000USD-2,896,189USD-2,530,947USD-2,416,481USD-3,236,763USD-2,987,366USD-1,719,381USD-1,644,502USD
    Depreciation1,098USD1,002USD911USD703USD608USD1,049USD1,589USD1,588USD
    Stock Based Compensation121,208USD320,125USD104,346USD99,513USD63,599USD155,547USD56,632USD57,675USD
    Other Non Cash Items134,270USD27,450USD73,489USD28,396USD61,867USD46,985USD30,531USD-65,661USD
    Change In Working Capital306,909USD-197,492USD-580,413USD-453,954USD1,263,677USD550,928USD-1,279,823USD-266,927USD
    Total Cash From Operating Activities-2,357,723USD-2,745,104USD-2,932,614USD-2,741,823USD-1,847,012USD-2,232,857USD-2,910,452USD-1,917,827USD
    Capital Expenditures-3USD-3,925USD-608USD-3,317USD0USD-3USD0USD-3USD
    Free Cash Flow-2,357,720USD-2,741,183USD-2,933,222USD-2,745,136USD-1,847,012USD-2,232,857USD-2,910,452USD-1,917,830USD
    Net Borrowings0USD0USD0USD0USD-1,372,873USD-686,436USD-686,436USD—
    Total Cash From Financing Activities451,000USD157,884USD8,360,887USD545,635USD1,324,669USD242,878USD3,293,437USD4,234,766USD
    Issuance Of Capital Stock509,277USD0USD8,921,766USD545,635USD2,697,542USD1,013,123USD58,436USD4,741,400USD
    Change In Cash-1,936,153USD-2,589,182USD5,427,665USD-2,199,501USD-522,343USD-2,020,663USD427,638USD2,320,991USD
    Begin Period Cash Flow7,936,153USD10,525,335USD5,097,670USD7,297,171USD7,819,514USD9,840,177USD9,412,539USD7,091,548USD
    End Period Cash Flow6,000,000USD7,936,153USD10,525,335USD5,097,670USD7,297,171USD7,819,514USD9,840,177USD9,412,539USD
    Total Cashflows From Investing Activities—-1,962USD-608USD-3,313USD————
    Other Cashflows From Investing Activities—-5,883USD———-3USD——
    Other Cashflows From Financing Activities—-1,372,873USD-562,370USD——-83,809USD3,921,437USD-506,634USD
    Unclassified Financing Cash Flow—1,530,757USD——————
    Investments——-608USD———0USD—
    Change To Account Receivables—————-3,236USD2,885USD148,644USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-11,080,380USD-8,266,576USD-6,140,730USD-13,798,339USD-12,550,973USD-17,688,522USD-9,355,592USD-8,899,975USD
    Depreciation3,224USD5,814USD6,554USD24,562USD34,161USD62,372USD54,450USD44,060USD
    Stock Based Compensation587,583USD329,815USD370,182USD333,389USD361,559USD409,933USD376,339USD380,886USD
    Other Non Cash Items191,202USD-124,262USD597,396USD366,255USD185,716USD5,252,484USD282,348USD1,483USD
    Change In Working Capital31,818USD-348,409USD-3,437,511USD425,112USD651,501USD509,307USD1,136,731USD1,228,915USD
    Total Cash From Operating Activities-10,266,553USD-8,403,618USD-8,604,109USD-12,649,021USD-11,739,620USD-11,454,426USD-7,509,567USD-7,244,631USD
    Capital Expenditures-5,883USD0USD-1USD-13,073USD-11,789USD-7,147USD-30,209USD-1,925USD
    Free Cash Flow-10,266,553USD-8,403,618USD-8,604,110USD-12,662,094USD-11,751,409USD-11,461,573USD-7,539,776USD-7,246,556USD
    Total Cashflows From Investing Activities-5,883USD——-13,073USD-11,789USD-7,147USD-24,709USD-925USD
    Net Borrowings-1,372,873USD-1,372,872USD-7,000,000USD0USD-6,149USD10,410,314USD-132,080USD-6,803USD
    Total Cash From Financing Activities10,389,075USD7,762,089USD3,663,506USD76,821USD19,058,000USD24,676,649USD4,005,455USD8,423,455USD
    Issuance Of Capital Stock12,164,943USD5,812,959USD11,666,633USD79,354USD19,705,647USD14,615,990USD4,142,456USD8,675,346USD
    Change In Cash116,639USD-626,644USD-4,913,457USD-12,684,282USD7,367,234USD13,255,955USD-3,563,009USD1,174,230USD
    Begin Period Cash Flow7,819,514USD8,446,158USD13,359,615USD26,043,897USD18,676,663USD5,420,708USD8,983,717USD7,809,487USD
    End Period Cash Flow7,936,153USD7,819,514USD8,446,158USD13,359,615USD26,043,897USD18,676,663USD5,420,708USD8,983,717USD
    Other Cashflows From Investing Activities-5,883USD—————5,500USD1,000USD
    Other Cashflows From Financing Activities-708,236USD3,322,000USD-923,773USD-2,490USD-641,497USD68,175USD-130,198USD-251,891USD
    Change To Account Receivables—219,897USD33,892USD23,759USD64,885USD815,061USD182,880USD-275,464USD
    Investments——0USD-13,073USD-11,789USD-7,147USD-24,709USD-925USD
    Dividends Paid———-43USD————
    Change To Inventory————-1,127,259USD1,157,160USD-1,968,565USD—
    Change To Liabilities————1,127,259USD-1,157,160USD1,968,565USD1,019,984USD
    Sale Purchase Of Stock—————4,987USD4,144,340USD8,675,350USD
    Exchange Rate Changes—————40,879USD-34,188USD-3,669USD
    Cash And Cash Equivalents Changes—————13,255,955USD-3,563,009USD1,174,230USD
    Unclassified Financing Cash Flow—————14,193,173USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    FY 2023Yearly · 2023-12-31SegmentBio Therapeutics395,124USD0001558370-25-003459
    FY 2023Yearly · 2023-12-31SegmentPublic Health Solutions444,235USD0001558370-25-003459
    Q2 2023Quarterly · 2023-06-30SegmentBio Therapeutics68,505USD0001558370-24-011740
    Q2 2023Quarterly · 2023-06-30SegmentPublic Health Solutions138,424USD0001558370-24-011740
    Q1 2023Quarterly · 2023-03-31SegmentBio Therapeutics155,365USD0001558370-24-007782
    Q1 2023Quarterly · 2023-03-31SegmentPublic Health Solutions101,813USD0001558370-24-007782
    FY 2022Yearly · 2022-12-31SegmentBio Therapeutics31,929USD0001558370-24-003402
    FY 2022Yearly · 2022-12-31SegmentPublic Health Solutions916,982USD0001558370-24-003402
    FY 2022Yearly · 2022-12-31ProductGrant698,911USD0001558370-24-003402
    FY 2022Yearly · 2022-12-31ProductLicense250,000USD0001558370-24-003402
    Q1 2022Quarterly · 2022-03-31ProductGovernment Contract50,000USD0001558370-23-009929
    Q1 2022Quarterly · 2022-03-31ProductGrant138,063USD0001558370-23-009929
    FY 2021Yearly · 2021-12-31ProductGovernment Contract33,351USD0001558370-23-005304
    FY 2021Yearly · 2021-12-31ProductGrant790,917USD0001558370-23-005304
    Q1 2021Quarterly · 2021-03-31ProductGovernment Contract33,351USD0001558370-22-008747
    Q1 2021Quarterly · 2021-03-31ProductGrant114,242USD0001558370-22-008747
    FY 2020Yearly · 2020-12-31SegmentBio Therapeutics117,369USD0001558370-22-004605
    FY 2020Yearly · 2020-12-31SegmentVaccines Bio Defense2,242,078USD0001558370-22-004605
    Q4 2020Quarterly · 2020-12-31SegmentBio Therapeutics0USDLegacy provider
    Q4 2020Quarterly · 2020-12-31SegmentVaccines Bio Defense320,796USDLegacy provider
    FY 2020Yearly · 2020-12-31ProductGovernment Contract1,930,533USD0001558370-22-004605
    FY 2020Yearly · 2020-12-31ProductGrant428,914USD0001558370-22-004605
    Q3 2020Quarterly · 2020-09-30SegmentBio Therapeutics64,345USD0001558370-21-015775
    Q3 2020Quarterly · 2020-09-30SegmentPublic Health Solutions544,466USD0001558370-21-015775
    Q2 2020Quarterly · 2020-06-30SegmentBio Therapeutics37,279USD0001558370-21-011669
    Q2 2020Quarterly · 2020-06-30SegmentPublic Health Solutions468,009USD0001558370-21-011669
    Q1 2020Quarterly · 2020-03-31SegmentBio Therapeutics15,745USD0001213900-21-027232
    Q1 2020Quarterly · 2020-03-31SegmentPublic Health Solutions908,807USD0001213900-21-027232
    FY 2019Yearly · 2019-12-31SegmentBio Therapeutics1,227,902USD0001213900-21-018698
    FY 2019Yearly · 2019-12-31SegmentVaccines Bio Defense3,402,014USD0001213900-21-018698
    Q4 2019Quarterly · 2019-12-31SegmentBio Therapeutics50,551USDLegacy provider
    Q4 2019Quarterly · 2019-12-31SegmentVaccines Bio Defense634,709USDLegacy provider
    Q3 2019Quarterly · 2019-09-30SegmentBio Therapeutics263,817USD0001213900-20-036345
    Q3 2019Quarterly · 2019-09-30SegmentVaccines Bio Defense991,087USD0001213900-20-036345
    FY 2018Yearly · 2018-12-31SegmentBio Therapeutics1,084,807USD0001213900-20-007959
    FY 2018Yearly · 2018-12-31SegmentVaccines Bio Defense4,156,641USD0001213900-20-007959
    FY 2017Yearly · 2017-12-31SegmentBio Therapeutics683,178USD0001213900-19-004865
    FY 2017Yearly · 2017-12-31SegmentVaccines Bio Defense4,749,294USD0001213900-19-004865
    FY 2015Yearly · 2015-12-31SegmentBio Therapeutics13,972USD0001213900-17-002845
    FY 2015Yearly · 2015-12-31SegmentVaccines Bio Defense8,754,418USD0001213900-17-002845
    FY 2014Yearly · 2014-12-31SegmentBio Therapeutics286,628USD0001213900-16-011833
    FY 2014Yearly · 2014-12-31SegmentVaccines Bio Defense6,756,388USD0001213900-16-011833

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.